{"changes":[],"country":"US","description":"Sirius Therapeutics is a clinical-stage biotech developing long-acting siRNA therapies for cardiovascular disease, led by SRSD107, a Factor XI inhibitor for thromboembolic disorders. It targets patients at risk of thrombosis where anticoagulants raise bleeding risk. Its edge is selective Factor XI silencing with minimal impact on normal hemostasis.","domain":"siriustx.com","employees":null,"founded":2021,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":32.71742,"lng":-117.162772,"location":"San Diego, United States","name":"Sirius Therapeutics","rounds":[{"amountQuarantined":false,"amountUsd":50000000,"currency":"USD","date":"2025-05-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-06-17","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"siriustx-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-06-17","status":"attributed","url":null},{"fact":"existence","publisher":"siriustx.com","retrievedAt":"2026-06-17","status":"self-reported","url":"https://siriustx.com"},{"fact":"description","publisher":"siriustx.com","retrievedAt":"2026-06-17","status":"self-reported","url":"https://siriustx.com"}],"stage":"series-b+","techStack":["hsts","nginx","openresty"],"totalRaisedUsd":100000000,"updatedAt":"2026-06-17"}